Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers

Nucleic Acids Research

Volumn 40, Issue 13, 2012, Pages 6319-6337

  Thiel, Kristina W ^a   Hernandez, Luiza I ^a   Dassie, Justin P ^a,b   Thiel, William H ^a   Liu, Xiuying ^a   Stockdale, Katie R ^a   Rothman, Alissa M ^a   Hernandez, Frank J ^a   McNamara, James O ^a   Giangrande, Paloma H ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN BCL 2; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL BASED GENE THERAPY; CELL SPECIFICITY; CELL TYPE; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG STRUCTURE; EMBRYO; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; INTERNALIZATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; RAT; RNA SEQUENCE; TARGET CELL DESTRUCTION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; CISPLATIN; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SELEX APTAMER TECHNIQUE;

EID: 84864447484     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gks294     Document Type: Article

References (114)

1. Jemal, A., Center, M.M., DeSantis, C. and Ward, E.M. (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev., 19, 1893-1907.
2. Jemal, A., Siegel, R., Xu, J. and Ward, E. (2010) Cancer statistics, 2010. CA Cancer J. Clin., 60, 277-300.
3. Jemal, A., Ward, E. and Thun, M. (2010) Declining death rates reflect progress against cancer. PLoS One, 5, e9584.
4. DeSantis, C., Jemal, A., Ward, E. and Thun, M.J. (2008) Temporal trends in breast cancer mortality by state and race. Cancer Causes Control, 19, 537-545.
5. Moasser, M.M. (2007) Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene, 26, 6577-6592.
6. Sundaresan, S., Penuel, E. and Sliwkowski, M.X. (1999) The biology of human epidermal growth factor receptor 2. Curr. Oncol. Rep., 1, 16-22.
7. Yarden, Y. (2001) Biology of HER2 and its importance in breast cancer. Oncology, 61(Suppl. 2), 1-13.
8. Harari, D. and Yarden, Y. (2000) Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene, 19, 6102-6114.
9. Muthuswamy, S.K., Gilman, M. and Brugge, J.S. (1999) Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo-and heterodimers. Mol. Cell. Biol., 19, 6845-6857.
10. Karunagaran, D., Tzahar, E., Beerli, R.R., Chen, X., Graus-Porta, D., Ratzkin, B.J., Seger, R., Hynes, N.E. and Yarden, Y. (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J., 15, 254-264.
11. Davies, E. and Hiscox, S. (2011) New therapeutic approaches in breast cancer. Maturitas, 68, 121-128.
12. Higa, G.M., Singh, V. and Abraham, J. (2010) Biological considerations and clinical applications of new HER2-targeted agents. Expert Rev. Anticancer Ther., 10, 1497-1509.
13. Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J. and Ullrich, A. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712.
14. Lemoine, N.R., Jain, S., Silvestre, F., Lopes, C., Hughes, C.M., McLelland, E., Gullick, W.J. and Filipe, M.I. (1991) Amplification and overexpression of the EGF receptor and C-erbB-2 proto-oncogenes in human stomach cancer. Br. J. Cancer, 64, 79-83.
15. De Vita, F., Giuliani, F., Silvestris, N., Catalano, G., Ciardiello, F. and Orditura, M. (2010) Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev., 36(Suppl. 3), S11-S15.
16. Sauter, G., Moch, H., Moore, D., Carroll, P., Kerschmann, R., Chew, K., Mihatsch, M.J., Gudat, F. and Waldman, F. (1993) Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res., 53, 2199-2203.
17. Stenman, G., Sandros, J., Nordkvist, A., Mark, J. and Sahlin, P. (1991) Expression of the ERBB2 protein in benign and malignant salivary gland tumors. Genes Chromosomes Cancer, 3, 128-135.
18. Tateishi, M., Ishida, T., Mitsudomi, T., Kaneko, S. and Sugimachi, K. (1991) Prognostic value of C-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur. J. Cancer, 27, 1372-1375.
19. Morris, S.R. and Carey, L.A. (2006) Trastuzumab and beyond: new possibilities for the treatment of HER2-positive breast cancer. Oncology, 20, 1763-1771; discussion 1771-1772, 1774-1776.
20. Valabrega, G., Montemurro, F. and Aglietta, M. (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol., 18, 977-984.
21. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C.C., Dantis, L., Sklarin, N.T., Seidman, A.D., Hudis, C.A., Moore, J. et al. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14, 737-744.
22. Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., Wolter, J.M., Paton, V., Shak, S., Lieberman, G. et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 17, 2639-2648.
23. Vogel, C.L., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., Slamon, D.J., Murphy, M., Novotny, W.F., Burchmore, M. et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol., 20, 719-726.
24. Hubalek, M., Brunner, C., Matthä, K. and Marth, C. (2010) Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien. Med. Wochenschr., 160, 506-512.
25. Montemurro, F., Donadio, M., Clavarezza, M., Redana, S., Jacomuzzi, M.E., Valabrega, G., Danese, S., Vietti-Ramus, G., Durando, A., Venturini, M. et al. (2006) Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist, 11, 318-324.
26. Montemurro, F., Valabrega, G. and Aglietta, M. (2006) Trastuzumab treatment in breast cancer. N. Engl. J. Med., 354, 2186; author reply 2186.
27. Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Anton, A., Lluch, A. et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol., 23, 4265-4274.
28. Nahta, R. and Esteva, F.J. (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res., 8, 215.
29. Nahta, R. and Esteva, F.J. (2006) Herceptin: mechanisms of action and resistance. Cancer Lett., 232, 123-138.
30. Nahta, R., Yu, D., Hung, M.C., Hortobagyi, G.N. and Esteva, F.J. (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol., 3, 269-280.
31. Camirand, A., Lu, Y. and Pollak, M. (2002) Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med. Sci. Monit., 8, BR521-BR526.
32. Nahta, R., Yuan, L.X., Zhang, B., Kobayashi, R. and Esteva, F.J. (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res., 65, 11118-11128.
33. Chakraborty, A.K., Liang, K. and DiGiovanna, M.P. (2008) Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res., 68, 1538-1545.
34. Ritter, C.A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J.A. and Arteaga, C.L. (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res., 13, 4909-4919.
35. Wheeler, D.L., Huang, S., Kruser, T.J., Nechrebecki, M.M., Armstrong, E.A., Benavente, S., Gondi, V., Hsu, K.T. and Harari, P.M. (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene, 27, 3944-3956.
36. Sergina, N.V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K.M. and Moasser, M.M. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature, 445, 437-441.
37. Wang, S., Huang, X., Lee, C.K. and Liu, B. (2010) Elevated expression of ERBB3 confers paclitaxel resistance in ERBB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene, 29, 4225-4236.
38. Brantley-Sieders, D.M., Zhuang, G., Hicks, D., Fang, W.B., Hwang, Y., Cates, J.M., Coffman, K., Jackson, D., Bruckheimer, E., Muraoka-Cook, R.S. et al. (2008) The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ERBB2 signaling. J. Clin. Invest., 118, 64-78.
39. Kwong, K.Y. and Hung, M.C. (1998) A novel splice variant of HER2 with increased transformation activity. Mol. Carcinog., 23, 62-68.
40. Siegel, P.M., Ryan, E.D., Cardiff, R.D. and Muller, W.J. (1999) Elevated expression of activated forms of Neu/ERBB-2 and ERBB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J., 18, 2149-2164.
41. Castiglioni, F., Tagliabue, E., Campiglio, M., Pupa, S.M., Balsari, A. and Menard, S. (2006) Role of exon-16-deleted HER2 in breast carcinomas. Endocr. Relat. Cancer, 13, 221-232.
42. Cittelly, D.M., Das, P.M., Salvo, V.A., Fonseca, J.P., Burow, M.E. and Jones, F.E. (2010) Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis, 31, 2049-2057.
43. Mitra, D., Brumlik, M.J., Okamgba, S.U., Zhu, Y., Duplessis, T.T., Parvani, J.G., Lesko, S.M., Brogi, E. and Jones, F.E. (2009) An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol. Cancer Ther., 8, 2152-2162.
44. Reed, J.C. (2006) Proapoptotic multidomain BCL-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ., 13, 1378-1386.
45. Kallel-Bayoudh, I., Hassen, H.B., Khabir, A., Boujelbene, N., Daoud, J., Frikha, M., Sallemi-Boudawara, T., Aifa, S. and Rebai, A. (2010) BCL-2 expression and triple negative profile in breast carcinoma. Med. Oncol., 28(Suppl. 1), s55-s61.
46. Ogretmen, B. and Safa, A.R. (1996) Down-regulation of apoptosis-related BCL-2 but not BCL-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int. J. Cancer, 67, 608-614.
47. Teixeira, C., Reed, J.C. and Pratt, M.A. (1995) Estrogen promotes chemotherapeutic drug resistance by a mechanism involving BCL-2 proto-oncogene expression in human breast cancer cells. Cancer Res., 55, 3902-3907.
48. Real, P.J., Cao, Y., Wang, R., Nikolovska-Coleska, Z., Sanz-Ortiz, J., Wang, S. and Fernandez-Luna, J.L. (2004) Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of BCL-2. Cancer Res., 64, 7947-7953.
49. Huang, Y., Ray, S., Reed, J.C., Ibrado, A.M., Tang, C., Nawabi, A. and Bhalla, K. (1997) Estrogen increases intracellular p26BCL-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res. Treat., 42, 73-81.
50. Kumar, R., Mandal, M., Lipton, A., Harvey, H. and Thompson, C.B. (1996) Overexpression of HER2 modulates BCL-2, BCL-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res., 2, 1215-1219.
51. Asanuma, H., Torigoe, T., Kamiguchi, K., Hirohashi, Y., Ohmura, T., Hirata, K., Sato, M. and Sato, N. (2005) Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res., 65, 11018-11025.
52. Hinnis, A.R., Luckett, J.C. and Walker, R.A. (2007) Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br. J. Cancer, 96, 639-645.
53. Xia, W., Bisi, J., Strum, J., Liu, L., Carrick, K., Graham, K.M., Treece, A.L., Hardwicke, M.A., Dush, M., Liao, Q. et al. (2006) Regulation of survivin by ERBB2 signaling: therapeutic implications for ERBB2-overexpressing breast cancers. Cancer Res., 66, 1640-1647.
54. Ryan, B.M., Konecny, G.E., Kahlert, S., Wang, H.J., Untch, M., Meng, G., Pegram, M.D., Podratz, K.C., Crown, J., Slamon, D.J. et al. (2006) Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann. Oncol., 17, 597-604.
55. Singh, M., Bleile, M.J., Shroyer, A.L., Heinz, D., Jarboe, E.A. and Shroyer, K.R. (2004) Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Appl. Immunohistochem. Mol. Morphol., 12, 296-304.
56. Foster, F.M., Owens, T.W., Tanianis-Hughes, J., Clarke, R.B., Brennan, K., Bundred, N.J. and Streuli, C.H. (2009) Targeting inhibitor of apoptosis proteins in combination with ERBB antagonists in breast cancer. Breast Cancer Res., 11, R41.
57. Jha, K., Shukla, M. and Pandey, M. (2012) Survivin expression and targeting in breast cancer. Surg. Oncol., 21, 125-131.
58. Lima, R.T., Martins, L.M., Guimarã es, J.E., Sambade, C. and Vasconcelos, M.H. (2004) Specific downregulation of BCL-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther, 11, 309-316.
59. Akar, U., Chaves-Reyez, A., Barria, M., Tari, A., Sanguino, A., Kondo, Y., Kondo, S., Arun, B., Lopez-Berestein, G. and Ozpolat, B. (2008) Silencing of BCL-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy, 4, 669-679.
60. Siddiqa, A., Long, L.M., Li, L., Marciniak, R.A. and Kazhdan, I. (2008) Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and BCL-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer, 8, 129.
61. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E. and Mello, C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806-811.
62. Bumcrot, D., Manoharan, M., Koteliansky, V. and Sah, D.W. (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol., 2, 711-719.
63. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J. et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 432, 173-178.
64. Pai, S.I., Lin, Y.Y., Macaes, B., Meneshian, A., Hung, C.F. and Wu, T.C. (2006) Prospects of RNA interference therapy for cancer. Gene Ther., 13, 464-477.
65. Petrocca, F. and Lieberman, J. (2011) Promise and challenge of RNA interference-based therapy for cancer. J. Clin. Oncol., 29, 747-754.
66. Sioud, M. (2011) Promises and challenges in developing RNAi as a research tool and therapy. Methods Mol. Biol., 703, 173-187.
67. Hao, J.H., Gu, Q.L., Liu, B.Y., Li, J.F., Chen, X.H., Ji, Y.B., Zhu, Z.G. and Lin, Y.Z. (2007) Inhibition of the proliferation of human gastric cancer cells SGC-7901 in vitro and in vivo using BCL-2 siRNA. Chin. Med. J., 120, 2105-2111.
68. McNamara, J.O. II, Andrechek, E.R., Wang, Y., Viles, K.D., Rempel, R.E., Gilboa, E., Sullenger, B.A. and Giangrande, P.H. (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol., 24, 1005-1015.
69. Ni, X., Zhang, Y., Ribas, J., Chowdhury, W.H., Castanares, M., Zhang, Z., Laiho, M., DeWeese, T.L. and Lupold, S.E. (2011) Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J. Clin. Invest., 121, 2383-2390.
70. Pecot, C.V., Calin, G.A., Coleman, R.L., Lopez-Berestein, G. and Sood, A.K. (2011) RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer, 11, 59-67.
71. Lares, M.R., Rossi, J.J. and Ouellet, D.L. (2010) RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol., 28, 570-579.
72. Manjunath, N. and Dykxhoorn, D.M. (2010) Advances in synthetic siRNA delivery. Discov. Med., 9, 418-430.
73. Higuchi, Y., Kawakami, S. and Hashida, M. (2010) Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs, 24, 195-205.
74. Dassie, J.P., Liu, X.Y., Thomas, G.S., Whitaker, R.M., Thiel, K.W., Stockdale, K.R., Meyerholz, D.K., McCaffrey, A.P., McNamara, J.O. II and Giangrande, P.H. (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol., 27, 839-849.
75. Lollini, P.L., Nicoletti, G., Landuzzi, L., De Giovanni, C., Rossi, I., Di Carlo, E., Musiani, P., Muller, W.J. and Nanni, P. (1998) Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int. J. Cancer, 77, 937-941.
76. Nanni, P., Pupa, S.M., Nicoletti, G., De Giovanni, C., Landuzzi, L., Rossi, I., Astolfi, A., Ricci, C., De Vecchi, R., Invernizzi, A.M. et al. (2000) p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer, 87, 186-194.
77. Kim, A., Liu, B., Ordonez-Ercan, D., Alvarez, K.M., Jones, L.D., McKimmey, C., Edgerton, S.M., Yang, X. and Thor, A.D. (2005) Functional interaction between mouse ERBB3 and wild-type rat C-neu in transgenic mouse mammary tumor cells. Breast Cancer Res., 7, R708-R718.
78. Liu, F.F., Stone, J.R., Schuldt, A.J., Okoshi, K., Okoshi, M.P., Nakayama, M., Ho, K.K., Manning, W.J., Marchionni, M.A., Lorell, B.H. et al. (2005) Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am. J. Physiol. Heart Circ. Physiol., 289, H660-H666.
79. Oakes, S.A., Scorrano, L., Opferman, J.T., Bassik, M.C., Nishino, M., Pozzan, T. and Korsmeyer, S.J. (2005) Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc. Natl Acad. Sci. USA, 102, 105-110.
80. Cerchia, L., Ducongé, F., Pestourie, C., Boulay, J., Aissouni, Y., Gombert, K., Tavitian, B., de Franciscis, V. and Libri, D. (2005) Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol., 3, e123.
81. Padilla, R. and Sousa, R. (1999) Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2'-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids Res., 27, 1561-1563.
82. Larkin, M.A., Blackshields, G., Brown, N.P., Chenna, R., McGettigan, P.A., McWilliam, H., Valentin, F., Wallace, I.M., Wilm, A., Lopez, R. et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics, 23, 2947-2948.
83. McNamara, J.O., Kolonias, D., Pastor, F., Mittler, R.S., Chen, L., Giangrande, P.H., Sullenger, B. and Gilboa, E. (2008) Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Invest., 118, 376-386.
84. Hernandez, F.J., Dondapati, S.K., Ozalp, V.C., Pinto, A., O'Sullivan, C.K., Klar, T.A. and Katakis, I. (2009) Label free optical sensor for Avidin based on single gold nanoparticles functionalized with aptamers. J. Biophotonics, 2, 227-231.
85. Hernandez, F.J., Kalra, N., Wengel, J. and Vester, B. (2009) Aptamers as a model for functional evaluation of LNA and 2'-amino LNA. Bioorg. Med. Chem. Lett., 19, 6585-6587.
86. Thiel, W.H., Bair, T., Wyatt Thiel, K., Dassie, J.P., Rockey, W.M., Howell, C.A., Liu, X.Y., Dupuy, A.J., Huang, L., Owczarzy, R. et al. (2011) Nucleotide bias observed with a short SELEX RNA aptamer library. Nucleic Acid Ther., 21, 253-263.
87. Reed, J.C. (1995) BCL-2: prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. North Am., 9, 451-473.
88. Huang, Y., Ibrado, A.M., Reed, J.C., Bullock, G., Ray, S., Tang, C. and Bhalla, K. (1997) Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia, 11, 253-257.
89. Reed, J.C., Miyashita, T., Takayama, S., Wang, H.G., Sato, T., Krajewski, S., Aimé-Sempé, C., Bodrug, S., Kitada, S. and Hanada, M. (1996) BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell. Biochem., 60, 23-32.
90. Pall, G.S. and Hamilton, A.J. (2008) Improved northern blot method for enhanced detection of small RNA. Nat. Protoc., 3, 1077-1084.
91. Song, E., Zhu, P., Lee, S.K., Chowdhury, D., Kussman, S., Dykxhoorn, D.M., Feng, Y., Palliser, D., Weiner, D.B., Shankar, P. et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol., 23, 709-717.
92. Vornlocher, H.P. (2006) Antibody-directed cell-type-specific delivery of siRNA. Trends Mol. Med., 12, 1-3.
93. Meade, B.R. and Dowdy, S.F. (2007) Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev., 59, 134-140.
94. Ikeda, Y. and Taira, K. (2006) Ligand-targeted delivery of therapeutic siRNA. Pharm. Res., 23, 1631-1640.
95. Eguchi, A. and Dowdy, S.F. (2009) siRNA delivery using peptide transduction domains. Trends Pharmacol. Sci., 30, 341-345.
96. Song, W.J., Du, J.Z., Sun, T.M., Zhang, P.Z. and Wang, J. (2010) Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small, 6, 239-246.
97. Toub, N., Malvy, C., Fattal, E. and Couvreur, P. (2006) Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed. Pharmacother., 60, 607-620.
98. Tamura, A. and Nagasaki, Y. (2010) Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. Nanomedicine, 5, 1089-1102.
99. Gao, W., Xiao, Z., Radovic-Moreno, A., Shi, J., Langer, R. and Farokhzad, O.C. (2010) Progress in siRNA delivery using multifunctional nanoparticles. Methods Mol. Biol., 629, 53-67.
100. Sioud, M. and Sorensen, D.R. (2003) Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun., 312, 1220-1225.
101. Pal, A., Ahmad, A., Khan, S., Sakabe, I., Zhang, C., Kasid, U.N. and Ahmad, I. (2005) Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int. J. Oncol., 26, 1087-1091.
102. Morrissey, D.V., Lockridge, J.A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V. et al. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol., 23, 1002-1007.
103. Wu, S.Y. and McMillan, N.A. (2009) Lipidic systems for in vivo siRNA delivery. AAPS J., 11, 639-652.
104. Thiel, K.W. and Giangrande, P.H. (2010) Intracellular delivery of RNA-based therapeutics using aptamers. Ther. Deliv., 1, 849-861.
105. Neff, C.P., Zhou, J., Remling, L., Kuruvilla, J., Zhang, J., Li, H., Smith, D.D., Swiderski, P., Rossi, J.J. and Akkina, R. (2011) An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci. Transl. Med., 3, 66ra6.
106. Pastor, F., Kolonias, D., Giangrande, P.H. and Gilboa, E. (2010) Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature, 465, 227-230.
107. Zhou, J. and Rossi, J.J. (2010) Aptamer-targeted cell-specific RNA interference. Silence, 1, 4.
108. Wheeler, L.A., Trifonova, R., Vrbanac, V., Basar, E., McKernan, S., Xu, Z., Seung, E., Deruaz, M., Dudek, T., Einarsson, J.I. et al. (2011) Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J. Clin. Invest., 121, 2401-2412.
109. Zhou, J., Swiderski, P., Li, H., Zhang, J., Neff, C.P., Akkina, R. and Rossi, J.J. (2009) Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res., 37, 3094-3109.
110. Zhou, J., Li, H., Li, S., Zaia, J. and Rossi, J.J. (2008) Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther., 16, 1481-1489.
111. Lupold, S.E., Hicke, B.J., Lin, Y. and Coffey, D.S. (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res., 62, 4029-4033.
112. Kraus, E., James, W. and Barclay, A.N. (1998) Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+T lymphocyte function. J. Immunol., 160, 5209-5212.
113. Zhou, J., Shu, Y., Guo, P., Smith, D.D. and Rossi, J.J. (2011) Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 Inhibition. Methods, 284-294.
114. Dominska, M. and Dykxhoorn, D.M. (2010) Breaking down the barriers: siRNA delivery and endosome escape. J. Cell Sci., 123, 1183-1189.